Program
DXC014
A development code.
Its studies are led by Hangzhou DAC Biotechnology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou DAC Biotechnology | 11 open or running | phase 1since Sep 10, 2025 | Sep 10, 2025 | Oct 20, 2030phase 1 · NCT07177937 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 10, 2025First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT07177937 · 150 planned · China
Ahead
- Oct 20, 2030Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07177937
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07177937Small Cell Lung Carcinoma · China | 1 | Recruiting | Oct 20, 2030 | 150 |
How it is read
Names in the registry
- “DXC014”, 1 entry
Codes read as this program: DXC014.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.